EMPA-REG OUTCOME: The Nephrologist's Point of View.

There is increasing evidence that sodium glucose cotransporter 2 (SGLT2) inhibitors have renoprotective effects, as demonstrated by the renal analyses from clinical trials including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME), CANagliflozin Treatment And Trial Analysis versus SUlphonylurea (CANTATA-SU), and the dapagliflozin renal study. The potential mechanisms responsible are likely multifactorial, and direct renovascular and hemodynamic effects are postulated to play a central role. This report reviews the renal outcomes data from key SGLT2 inhibitor clinical trials, discusses the hypotheses for SGLT2 inhibitor-associated renoprotection, and considers the main renal safety issues associated with SGLT2 inhibitor treatment.

• Publication year

  2017

• Venue

  American Journal of Medicine

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjmed.2017.04.007PMID 28526179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?

  2017influential reference
• Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

  2017cited by this paper
• Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.

  2017influential reference
• Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

  2017cited by this paper
• Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

  2016influential reference
• The effect of dapagliflozin on renal function in patients with type 2 diabetes

  2016cited by this paper
• Diabetes and Cause-Specific Mortality in Mexico City.

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016influential reference
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2016influential reference
• Glucagon and heart in type 2 diabetes: new perspectives

  2016cited by this paper
• Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury

  2016cited by this paper
• Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

  2015cited by this paper
• Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

  2015cited by this paper
• Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis

  2015cited by this paper
• Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets

  2015influential reference
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

  2015cited by this paper
• Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea.

  2015cited by this paper
• Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths

  2015cited by this paper
• Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

  2014influential reference
• Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

  2014cited by this paper
• Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

  2014cited by this paper
• Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

  2014cited by this paper
• Diabetic kidney disease: from physiology to therapeutics

  2014cited by this paper
• Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002.

  2014cited by this paper
• Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

  2014influential reference
• Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.

  2014cited by this paper
• The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

  2014cited by this paper
• Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

  2013cited by this paper
• Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.

  2013cited by this paper
• Epidemiology of Diabetes and Diabetes Complications in the Elderly: An Emerging Public Health Burden

  2013cited by this paper
• Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

  2013cited by this paper
• Uric acid and chronic kidney disease: which is chasing which?

  2013cited by this paper
• Combined angiotensin inhibition for the treatment of diabetic nephropathy.

  2013cited by this paper
• Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

  2013cited by this paper
• Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

  2013cited by this paper
• Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans

  2013cited by this paper
• Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

  2013cited by this paper
• Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

  2012cited by this paper
• Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

  2012cited by this paper
• A study of the natural history of diabetic kidney disease (DKD).

  2012cited by this paper
• The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

  2012cited by this paper
• Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

  2008influential reference
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Hypoxia-inducible factors in the kidney.

  2006cited by this paper
• Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

  2005cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Glucagon and the circulation.

  1983cited by this paper
• Original Report: Patient-oriented, Translational Research Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

  year unknowncited by this paper

• Canagliflozin: A Comprehensive Review of Advances in Preclinical Research

  2025cites this paper
• Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials

  2025cites this paper
• Impact of SGLT2 inhibitors on erythropoiesis and iron exchange in patients with diabetes mellitus and chronic heart failure

  2024cites this paper
• The Effect of Empagliflozin on Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway in Patients with Type 2 Cardiorenal Syndrome

  2024cites this paper
• Molecular imaging along the heart-kidney axis

  2024cites this paper
• Optimizing kidney and cardiovascular protection in an era of multiple effective treatments

  2024cites this paper
• Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders

  2023cites this paper
• Aktuelle Strategien zur kardiovaskulären Risikoreduktion bei CKD

  2023cites this paper
• SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: systematic review and meta-analysis

  2023cites this paper
• Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease

  2023cites this paper
• Significance of Kidney Disease in Cardiovascular Disease Patients.

  2023cites this paper
• Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease

  2023cites this paper
• Sodium‐glucose co‐transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction

  2022cites this paper
• New Insights into the Use of Empagliflozin—A Comprehensive Review

  2022cites this paper
• Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis

  2022influential citation
• Renal outcomes with sodium-glucose cotransporters 2 inhibitors

  2022cites this paper
• Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials

  2022cites this paper
• Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients

  2022cites this paper
• Therapeutic Advances in Diabetic Nephropathy

  2022cites this paper
• Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease

  2021cites this paper
• EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021)

  2021cites this paper
• Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease

  2021cites this paper
• Gliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura

  2021cites this paper
• Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress

  2021cites this paper
• Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease.

  2021cites this paper
• Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first‐line oral therapy for type 2 diabetes: A claims‐based observational cohort study

  2021cites this paper
• Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures

  2021cites this paper
• ЕВРАЗИЙСКИЕ РЕКОМЕНДАЦИИ ПО ПРОФИЛАКТИКЕ И ЛЕЧЕНИЮ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У БОЛЬНЫХ С ДИАБЕТОМ И ПРЕДИАБЕТОМ (2021)

  2021cites this paper
• Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

  2021cites this paper
• Canagliflozin To Slow Renal Insufficiency Progression in Non-Diabetic Chronic Kidney Disease

  2020cites this paper
• Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension

  2020cites this paper
• A Review of the Renoprotective Effects of Novel Antidiabetic Agents

  2020cites this paper
• Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease

  2020cites this paper
• Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney

  2020influential citation
• Diagnosis and treatment of type 2 diabetes mellitus in patients with chronic kidney disease and eGFR < 60 mL/min - a position statement of the Polish Society of Nephrology Working Group on Metabolic and Endocrine Disorders in Kidney Diseases.

  2020cites this paper
• Long‐term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis

  2020cites this paper
• Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results

  2020cites this paper
• [Sodium glucose co-transporter 2 inhibitors in heart failure therapy].

  2020cites this paper
• Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.

  2020cites this paper
• Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications

  2020cites this paper
• Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure

  2020cites this paper
• Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

  2020cites this paper
• Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement

  2020cites this paper
• Cardiorenal Syndrome in Type 2 Diabetes Mellitus - Rational Use of Sodium-glucose Cotransporter-2 Inhibitors.

  2020cites this paper
• University of Dundee Renal and Cardiovascular Effects of SGLT2 inhibition in combination with loop Diuretics in patients with Type 2 Diabetes and Chronic Heart Failure Mordi,

  2020cites this paper
• Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Recent advances in the pathogenesis of microvascular complications in diabetes

  2019cites this paper
• Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity

  2019cites this paper
• A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion

  2019cites this paper
• The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit

  2019cites this paper
• Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

  2019cites this paper
• Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view.

  2019cites this paper
• Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes

  2019cites this paper
• Optimizing Glycemic Control of Diabetes Mellitus in Older Adults – A Tailored Approach

  2019cites this paper
• Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development

  2019cites this paper
• Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes

  2019influential citation
• Pre-treatment with Empagliflozin ameliorates Cisplatin induced acute kidney injury by suppressing apoptosis.

  2019cites this paper
• Role of Empagliflozin and Linagliptin Combination in Diabetic Kidney Disease

  2019cites this paper
• The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury

  2019cites this paper
• An update on the safety of SGLT2 inhibitors

  2019cites this paper
• How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

  2019cites this paper
• The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors

  2019cites this paper
• Renal effects of sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment

  2019influential citation
• Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.

  2018cites this paper
• Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page

  2018cites this paper
• Glucosuria and all-cause mortality among general screening participants

  2018cites this paper
• Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit

  2018cites this paper
• Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

  2018cites this paper
• Renal fibrosis: Primacy of the proximal tubule.

  2018cites this paper
• Próba kliniczna EMPA-REG OUTCOME z zastosowaniem empagliflozyny — nowa era w terapii cukrzycy typu 2

  2018influential citation
• Sodium-Glucose Transporter Inhibitors and Diabetic Nephropathy in Humans and Animal Model

  2018influential citation
• Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease

  2018cites this paper
• Protection of the kidney with sodium–glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials

  2018cites this paper
• Preventing and treating kidney disease in patients with type 2 diabetes

  2018cites this paper
• Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.

  2018cites this paper
• Empagliflozin: A Review in Type 2 Diabetes

  2018cites this paper
• Chronisches Nierenversagen – Update 2018

  2018cites this paper
• SGLT2 inhibitors and the kidney: Effects and mechanisms.

  2018cites this paper
• Decision modelling for the evaluation of diabetes outcomes

  2017cites this paper
• What is new in diabetic nephropathy during the last decade?

  2017cites this paper
• EMPA-REG OUTCOME: The Cardiologist's Point of View.

  2017cites this paper
• A 2-es típusú cukorbetegek személyre szabott kezelése: fókuszban a korai SGLT2-gátló terápia

  2017cites this paper
• Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

  2017cites this paper
• EMPA-REG OUTCOME: The Endocrinologist's Point of View.

  2017cites this paper
• Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

  2017cites this paper
• EMPA-REG OUTCOME: The Cardiologist's Point of View.

  2017cites this paper
• Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.

  2017cites this paper
• EMPA-REG OUTCOME: The Endocrinologist's Point of View.

  2017cites this paper
• Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.

  2017cites this paper
• Die Nephrologie

  year unknowncites this paper